Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

http://medical-dictionary.thefreedictionary.com/lymphoproliferativeSearch in Google Scholar

Primic Žakelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, Zakotnik B and Žagar T, editors. Cancer incidence in Slovenia 2006. Ljubljana: Institute of Oncology Ljubljana, Cancer registry of Republic of Slovenia; 2009.Search in Google Scholar

Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2006; 66: 791-820.10.2165/00003495-200666060-0000516706552Search in Google Scholar

Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008; 59: 237-50.10.1146/annurev.med.59.060906.22034518186705Search in Google Scholar

Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654-61.10.1200/JCO.2004.07.17015159414Search in Google Scholar

Nickenig C, D reyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014-22.10.1002/cncr.2209316878325Search in Google Scholar

Sebban C, Mo unier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540 Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590-6.10.1200/JCO.2005.03.795216575010Search in Google Scholar

Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590-6.10.1200/JCO.2005.03.7952Search in Google Scholar

Huic D, Mutvar A, Kinda-Basic S, Aurer I, Ciglar M, Grosev D, et al. Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study. Radiol Oncol 2009; 43: 258-63.10.2478/v10019-009-0024-xSearch in Google Scholar

Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, et al. Longterm follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2010; 28: 822-9.10.1200/JCO.2009.22.781920026809Search in Google Scholar

Samardziski M, Zafiroski G, Tolevska C, Kalicanin-Markovska M, Doncovska D, Anevska V, et al. Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results. Radiol Oncol 2009; 43: 187-94.Search in Google Scholar

Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 2008; 46: 213-23.10.1016/j.rcl.2008.03.00318619377Search in Google Scholar

Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-31.10.1182/blood-2008-04-15318918799723Search in Google Scholar

Jezeršek Novaković B, Benigar A. Treatment of NonHodgkin's lymphomas with rituximab in Slovene patients. Med Oncol 2010; 27: 167-76.10.1007/s12032-009-9188-xSearch in Google Scholar

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.10.1038/sj.onc.1206939Search in Google Scholar

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.10.1182/blood-2004-08-3175Search in Google Scholar

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-32.10.1182/blood-2005-01-0016Search in Google Scholar

Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-92.10.1200/JCO.2006.06.4618Search in Google Scholar

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.10.1200/JCO.2005.09.131Search in Google Scholar

Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-7.10.1200/JCO.2005.05.1003Search in Google Scholar

Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.10.1016/S1470-2045(06)70664-7Search in Google Scholar